FINWIRES · TerminalLIVE
FINWIRES

摩根士丹利季度業績超乎預期，投資銀行和交易業務均有成長。

-- 摩根士丹利（MS）週三公佈的第一季業績超出預期，投資銀行和交易業務的強勁成長推動營收創下歷史新高。 截至3月的第一季，每股盈餘從去年同期的2.60美元躍升至3.43美元，超過FactSet調查的3美元的預期。營收成長16%至205.8億美元，高於分析師預期的197.4億美元。 機構證券部門營收從去年同期的89.8億美元增至107.2億美元，主要得益於投資銀行業務36%的飆升，達到21.2億美元。股票和固定收益部門也分別實現了25%和29%的強勁成長。 財富管理業務營收成長16%，達到創紀錄的85.2億美元。 執行長泰德·皮克在一份聲明中表示：“機構證券業務受益於強勁的客戶參與度和全球市場的穩健表現。” “財富管理業務持續保持增長勢頭，淨新增資產達1180億美元，費用型資產流入達540億美元。” 摩根士丹利股價盤中上漲5.5%，今年迄今已累計上漲8.9%。 美國銀行（BAC）週三公佈了第一季業績，其獲利和營收均超出市場預期，投資銀行和資產管理費用均實現了兩位數成長。 摩根大通（JPM）和花旗集團（C）週二公佈的第一季業績均優於預期，而富國銀行（WFC）的營收則低於市場預期。週一，高盛（GS）公佈的財務數據也高於華爾街預期。

Price: $192.50, Change: $+9.16, Percent Change: +5.00%

Related Articles

Asia

National Australia Bank Shares Down After Resolution of Union Court Proceedings

National Australia Bank (ASX:NAB) shares were down about 1% in recent Monday trade following a Friday settlement with the Finance Sector Union of Australia to resolve court proceedings related to excessive additional working hours for employees.The settlement, reached on a without-admissions basis through mediation, includes the establishment of a health, safety, and well-being framework to mitigate the risks linked to working additional hours, and calls for greater oversight of such risks.The union and the bank said in a joint statement that they are "committed to continuing to work together to ensure fair and sustainable outcomes for all [National Australia Bank] employees."

$ASX:NAB
Asia

Clinuvel Pharmaceuticals Says FDA Removes Post-Authorization Requirement for Implant

Clinuvel Pharmaceuticals (ASX:CUV) said the US Food and Drug Administration (FDA) removed a requirement for a post-authorization phase one study on cardiac repolarization in relation to its Scenesse implant upon reviewing its long-term safety profile, according to a Monday filing with the Australian bourse.Scenesse is used to treat patients with erythropoietic protoporphyria, a disease that causes intolerance to light.The FDA concluded that the study was no longer needed since it would not yield valuable safety information, the filing said.

$ASX:CUV
Asia

XRF Scientific Completes Acquisition of Combustion Gas Analysis Business

XRF Scientific (ASX:XRF) has completed the acquisition of the combustion gas analysis business from Bruker AXS, according to a Monday Australian bourse filing.The company entered a binding agreement to acquire the combustion gas analysis business for $4 million upfront plus a potential $1 million earnout based on 7% of net revenue over three years, an earlier filing showed.

$ASX:XRF